Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
Rhea-AI Summary
Autolus Therapeutics (Nasdaq: AUTL) will participate in the Jefferies Global Healthcare Conference in London. CEO Dr. Christian Itin will appear in a fireside chat on Tuesday, November 18, 2025 at 7:30 AM EST / 12:30 PM GMT. A live webcast will be available on the company’s Events page and a replay will be archived on the website for 90 days after the presentation.
The presentation covers company updates and investor engagement; webcast access is via the company investor relations site.
Positive
- None.
Negative
- None.
News Market Reaction – AUTL
In the Nov 14 session, AUTL gained 7.03%, reflecting a notable positive market reaction. Argus tracked a peak move of +4.5% during that session. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON and GAITHERSBURG, Md., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in the Jefferies Global Healthcare Conference in London.
Autolus Chief Executive Officer Dr. Christian Itin will present in a Fireside Chat on Tuesday, November 18, 2025 at 7:30am EST / 12:30pm GMT.
A webcast of the fireside chat will be available on the “Events” page in the “Investor Relations & Media” section of the Company’s website at https://www.autolus.com/investor-relations-media/events/. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.
About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.
Contact:
Amanda Cray
+1 617-967-0207
a.cray@autolus.com
